ClinicalTrials.gg
Not yet recruitingNCT07523607Updated Apr 13, 2026

FAP PET/CT for Staging Patients With Breast Cancer

A Phase 2 interventional study of 68Ga-FAP-2286 in Breast Cancer Detection, sponsored by Odense University Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Odense University Hospital · Phase 2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the clinical utility of [68Ga]Ga-FAP-2268 PET/CT for disease staging and assessment in patients with high-risk primary breast cancer. By targeting fibroblast activation protein (FAP), this novel imaging approach may offer improved tumor visualization compared to conventional imaging, which may help improve treatment planning.

02

Conditions studied

  • Breast Cancer Detection

Browse trials for

Keywords

  • Breast cancer
  • PET/CT
  • FAP
  • FAPI
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 65 is close to the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and females ≥ 18 years
  • -verified newly diagnosed breast cancer
  • Can read and understand Danish
  • Capable of providing written and
  • Undergoing a routine [¹⁸F]FDG PET/CT scan as part of the clinical standard diagnostic workup

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Not able to participate in the conduct of the scan due to any reason ( e.g., claustrophobia or inability to lie still for entire imaging time)
  • Ongoing oncological treatment for another cancer
  • History of allergic reactions / attributed to [⁶⁸Ga]Ga-FAP-2286.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    68Ga-FAP-2286 PET/CT Imaging

    Patients undergo intravenous administration (200 MBq) of 68Ga-FAP-2286 followed by PET/CT imaging for staging of high-risk primary breast cancer. A baseline scan is performed prior to initiation of therapy. Patients receiving neoadjuvant chemotherapy undergo an additional scan prior to surgery.

    Drug: 68Ga-FAP-2286

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with nodal and distant metastases detected by [⁶⁸Ga]Ga-FAP-2286 PET/CT at baseline (pre-treatment staging)

    Nodal and distant metastases will be identified on a per-patient and per-lesion basis using \[⁶⁸Ga\]Ga-FAP-2286 PET/CT in 65 patients undergoing baseline staging. PET/CT images will be read blinded. The reference standard is histopathology where available; if histopathology is not available, a composite of clinical and imaging follow-up will be used. Sensitivity and specificity with 95% confidence intervals will be calculated per patient and per lesion.

    Time frame: Baseline (pre-treatment). Inclusion period 1 year.

  2. Concordance of [⁶⁸Ga]Ga-FAP-2286 PET/CT with surgical pathology for axillary lymph node status after neoadjuvant therapy (restaging)

    In approximately 50 patients undergoing post-neoadjuvant therapy PET/CT prior to surgery, axillary lymph node status will be classified as (a) uptake on PET/CT with histologically confirmed residual disease, or (b) no uptake on PET/CT with pathological complete response (pCR). PET/CT images will be read blinded, with surgical pathology as the gold standard. Concordance (proportion correctly classified) and appropriate concordance statistics will be calculated.

    Time frame: Post-therapy/ pre-surgery scan, about 6 month after baseline scan.

Secondary outcomes

  1. Number of patients with TNM stage or MDT treatment decision changes after [⁶⁸Ga]Ga-FAP-2286 PET/CT

    For baseline staging (approximately 65 patients), TNM stage and MDT treatment decisions will be compared before and after availability of \[⁶⁸Ga\]Ga-FAP-2286 PET/CT results. Proportions of patients with changes will be reported with 95% confidence intervals (Wilson-score method). Data will be extracted from eCRF documentation.

    Time frame: Baseline (pre-PET/CT) and up to 7 days post-PET/CT at MDT review

  2. Inter-reader agreement of [⁶⁸Ga]Ga-FAP-2286 PET/CT lesion detection, BI-RADS-like scoring, and SUV/TBR quantification

    All baseline scans will be independently read by two blinded physicians. Lesions will be scored using a standardized Likert-type scale for presence, risk of malignancy, and clinical relevance on a per-patient and per-lesion basis. Quantitative uptake will be measured using SUVmax, SUVmean, and lesion-to-background ratio (LBR). Interobserver agreement for categorical measures will be quantified with (linearly weighted) Cohen's kappa; for continuous measures, Bland-Altman analysis and intraclass correlation coefficients (ICC) will be used.

    Time frame: Baseline (initial reading) and up to 18 months post-baseline for blinded second reading

  3. Incidence, severity, and causality of AEs, SAEs, and SUSARs after [⁶⁸Ga]Ga-FAP-2286 administration

    Adverse events will be recorded for 48 hours post-injection, assessed per CTCAE v6.0. Data will include incidence, severity, and causality of AEs, SAEs, and SUSARs. Descriptive statistics will summarize findings by type, severity, and relation to the tracer.

    Time frame: From tracer injection to 48 hours post-injection

  4. Lesion-level [⁶⁸Ga]Ga-FAP-2286 uptake patterns (SUVmax, SUVmean, LBR) across tumor subtypes and anatomical sites

    ROI-based quantification will be performed for primary tumors, axillary lymph nodes, and suspected distant lesions. Uptake metrics (SUVmax, SUVmean, LBR) will be summarized per lesion, stratified by histological and molecular subtype, and anatomical site using descriptive statistics.

    Time frame: Baseline and up to approximately 6 months post-baseline.

  5. Frequency, type, and clinical impact of incidental findings on [⁶⁸Ga]Ga-FAP-2286 PET/CT

    Incidental findings will be documented per patient at baseline , and for patients receiving neoadjuvant chemotherapy, on pre-surgery scans. This will include numbers of incidental findings, type, and clinical consequences. Proportions of incidental findings leading to additional diagnostic procedures (e.g., biopsy, MRI, CT) or clinical intervention will be reported descriptively.

    Time frame: Baseline and up to approximately 6 months post-baseline (Pre-surgery, for patients receiving NACT)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jan 2028, 19 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 19 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Apr 13, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07523607
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Sara E Dahlsgaard-Wallenius, MD
Contact
sara.elisabeth.wallenius@rsyd.dk
+45 53 57 45 55

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium (68GA) rofapitide tetraxetan

Start the discussion